Outlook: Boston Scientific forecasts net sales growth of approximately 15%-17% in 2025 on a reported basis and around 12%-14% on an organic basis, compared to prior guidance of 12.5%-14.5% and 10% ...

For the full year, Boston Scientific sees adjusted EPS of $2.87 to $2.94 and sales up 15% to 17%, above Visible Alpha projections.

Boston Scientific developed a system: Set aside 10 percent of revenue for research and development, including to advance already acquired technologies, and devote much of its profits to new deals.

Boston Scientific's earnings growth may slow to the low teens, making current P/E multiples hard to justify. See why BSX stock is a Hold.

Boston Scientific on Tuesday said it would pay $27.50 a share in cash for Silk Road, a 27% premium to Monday’s closing price of $21.67 for the Sunnyvale, Calif., company.

Boston Scientific shares rose 6.3% as of 11:26 a.m. ET to $73.34 after earlier hitting an all-time high of $74.39. They are up about 27% this year.

Boston Scientific has made acquisitions to drive growth, including the recent $3.4 billion acquisition of Axonics. After a re-rating, Boston Scientific Corporation shares look a bit extended here.

The companies said on Monday that Axonics had agreed to be bought for $71 a share. Boston Scientific said the deal gave Axonics an equity value of $3.7 billion and an enterprise value of $3.4 billion.

Boston Scientific Corp. agreed to pay $71 a share in cash for medical technology firm Axonics Inc., a maker of devices to treat urinary and bowel dysfunction. The purchase price comes to an equity ...

Boston Scientific said it will buy Axonics, a device company treating urinary and bowel disorders, on Monday. The deal is worth $3.7 billion. It’s the first billion-dollar medical device deal of ...

Boston Scientific, Inc. BSX recently received FDA approval for an expanded indication of the WaveWriter Alpha Spinal Cord Stimulator (“SCS”) Systems. With this approval, the system will be ...